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The human IL-1 receptor antagonist (IL-lra) was produced in a high yield E, coil expression system, and was purified in a rapid two-step 
purification. This recombinant IL-lra molecule possess,zxl fu l binding activity to the IL-I receptor (type I) and totally inhibited IL-l-indueed PGE: 
production by human dermal fibroblasts. Radioalkylation a d analysis of Vg.derived IL-lra peptides indicate that the four cysteincs present in 
the IL-lra are not disulphide.linked. 
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1. INTRODUCTION 
The IL-I receptor antagonist (IL-lra) was originally 
described as a molecule which inhibits the activity of 
IL-I [1]. eDNA [2] and genomic DNA clones have been 
isolated and characterized [3,4]. Using a polymorphism 
within the second intron [5] the chromosomal localiza- 
tion has been established by linkage analysis [6] and 
independently by in situ hybridization [4], showing that 
the genes for IL-lra, 1L-I~ and IL-lfl are located close 
to each other on chromosome two. Control of IL-1 
expression level and/or therapeutic inhibition of the 
binding to the receptor may be important in the treat- 
ment of autoimmune and other IL-l-mediated inflam- 
matory diseases, and IL-lra may play an important role 
in development of such therapy [7]. 
In this study we describe a high yield expression of 
1L-lra in E. coli, which produces a functionally fully 
active protein which is easy to purify. In addition our 
results indicate that the four eysteines are not di- 
sulphide-linked. 
2. MATERIALS AND METHODS 
2.1. Vector construction 
The coding region for the IL-lra (residues 3-152, numbering ac- 
cording to [2] was amplified from U937 eDNA by PCR with the 
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introduction of an additional glycine residue and a BamHl restriction 
site at the 5' end and an EcoRI site at the 3' end (5' oligonaeleotide 
CGG GAT CCG GGA GAA AAT CCA GCA AGA TG; 3' oligonu- 
cl¢otid¢ COG AAT TCC CCT ACT COT CCT CCT GGA). Using 
these primers the mature recombinant protein differs from the native 
protein in that its N-terminal sequence is GSGRK rather than 
RPSGRK as found in the native protein. The PCR product was 
introduced into the fusion protein expression vector pGEX-Zr [8] and 
transformed in the E. colistrain NM554. The fusion partner glutathi- 
one S-transferas¢ (GST) can be cleaved off after expression, using 
thrombin0 to obtain an authentic recombinant IL-I ra protein. 
An overnight bacterial cultur~ was diluted 1:10 in fresh LB.medium 
and grown for I h at 37°C at which point IPTG was added (0.1 raM) 
and crown for a further O h. The cells were pelctted and resuspended 
in 1/50 of the starting volume in lysis buffer (PB$ containing lysozyme, 
0.2 mg/ml; DNase, 10 mg/ml; Triton X-100, 0,1% (v/v); PMSF, 0.1 
mM; iodoacetamide, 5 mg/ml; be~id ine ,  50 raM; EDTA, 5 raM; 
PUS i.~ NaCI 150 raM; Na,HPO~ 16 raM; NaH:PO.~ 54mM; pH 7.2) 
for I h and thereafter sonicated 3 x 20 a using an MSE sonieator. After 
centrifugation (10,000 × g; 20 rain) the supernatant was incubated with 
glutathion¢-agaros¢ beads [8] (Sigma G-4510) at 4°C overnight. After 
washing the beads with PBS, the fusion protein was directly cleaved 
on the beads with human thrombin (1 Unit per I mg protein) (Sigma 
"1"-3010) at 37*(2 for4 h. The beads were spun down and the recombi- 
nant IL-lra was purified by passing through a Scphacryl HR SI00 
(Pharmacia) column of 950 mm× 25 mm diam. at a flow rate of 1,2 
mi/min using 10 mM potasshm phosphate (pH 7.3) with 0.05% (w/v) 
sodium azide as loading and elution buffer. Fractions were colkcled 
and the presence of the recombinant I L-ira was checked by the OD.~ 
and confirmed by SDS-PAGE. The purified material was also sub- 
jeered to N.terminal amino acid sequence analysis (Applied l~ios~s- 
terns 470A) and electrospray mass spectrometry t'VG 810 Q quad- 
rapole mas~ spectrometer). These techniques confirm=:! timt the re- 
combinant material has been purified to > 98% and has the expected 
mol.wt, of 16,930 and expected N-terminal sequence. The extinction 
coc~cie~t ~t 280 nm (! em, 1 mg/ml) was calculated b.v the method 
of Perkins [9] as 0.96. This value was 'used to calculate protein concen- 
tration. 
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2,2. Recw)tor binding studies with recomb&ant IL.h'a 
EL4.6.I.dI0 cells were resuspended at 107 cells/ml in binding me- 
dium (RPMI 1640, 5% FCS, 20 mM I-IEPES pH 7.2), and 50.ul of cell 
suspension was added to each well of a 96-well filtratioa plate (Mil- 
lipore Muhiscreen). To each well 50 ~tl of ~'al-humun-lL-l" (NEN 
Dupont) at a final concentrations of 50 pM was added. Unlabelh,,d 
human IL-lfl and human IL-lra were serially diluted in binding me- 
dium, and 50,ul aliquots of unlabelled ligand were added to each well 
at the final concentration indicated on Fig. 2a. Receptor binding was 
allowed to proce~ to equilibrium at 4°C. The plates were washed four 
times in binding medium by vacuum filtration, and the filters subse- 
quently punched out and counted for bound radioactivity. 
2.3. Inhibition of PGE, production by IL-h'a 
The induction of PGE: production by IL- I was assayed as described 
previously [10]. Briefly, human dermal fibroblasts were s~ded at 10 ~ 
cells per well in a 96-well plate. The cells wer~ maintained for 3 days 
in culture to reach confluence, then washed with fresh medium and 
stimulated for 24 h with 50 pM human IL-lfl in the presence of 
increasing concentrations of IL-lra. At the end of the 24-h period, the 
culture supernatant was r~moved and immediately assayed Ibr PGE: 
content using a scintillation proximity assay (Amersham). 
3. RESULTS AND DISCUSSION 
The human IL-lra was expressed as a GST-fusion 
protein in an E. coli expression system. After a simple 
two-step purification a yield of approximately 15 mg 
recombinant IL-lra per litre of culture was obtained 
(Fig. 1). Due to the introduced thrombin cleavage site 
the IL-lra starts with a glycine and the first two amino 
acids of the reported protein sequence [2] are absent. 
N-terminal amino acid sequencing and mass spectrome- 
tery, which indicated a precise mol.wt of 16,930 Da, 
confirmed the correct expression of the IL-1 ra molecule. 
In order to establish the binding activity of  the recom- 
binant protein, the IL-ra molecule was tested in an IL-1 
receptor binding competition assay. The binding activ- 
ity of the recombinant IL-lra was only marginally less 
than that of 1L-1/~, indicating a similar affinity for bind- 
ing to the type I IL-I receptor (Fig. 2a). To investigate 
2.4. Cysteh~e r sidttes in recombinant I -Ira 
1 L- Ira (30.ug) was dissolved into i ml of 0. [ M Trls-HCl. pH 8 and 
incubated at 37*C for 16 h with 3 pg endoproteinase GIu-C (V8 
pro,ease) (Boehringer-Sequencer grade) which cleaves after glutami¢ 
acid. The digested peptides plus a sample of starting material were run 
on a Brownlee Aquapore RP300 column (C8) in O.1% TFA and pep- 
tides were eluted with a 2-50% gradient of acetonitrilc over 50 min, 
then a 50-90% acetonitrile gradient over the next 15 rain. The N 
termini of the main l~ptides were sequenced on an Applied Biosystems 
470A protein sequencer with online PTH analysis, to determine 
whether pairs of disulphide linked peptides were present. 
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Fig. I. SDS-PAGE analysis or" the recombinant IL-Ira. Lane I, total 
E. coil lysate. The major band represents he GST-IL-Ira fusion pro. 
tein; lane 2, fusion protein attached to ~lutathion¢ agaroue heads after 
incubatio, with the total E. cu~i lysat-; lane 3. mat~rlal remaining 
bound to the glutathione agarose beads after thrombin cleavage. Only 
the GST is still bound to the brads; lane 4, supgrnatant after thrombin 
cleavage, containing the IL-lra. 
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Fig. 2. Th ,~ recombinant IL-lra was tested in a competition assay for 
receptor binding activity. ~"Sl-labclled IL-I~ was incubated with EL4 
cells in the presence of increasing concentrations of unlabelled IL-lra 
(open circles) or IL-lp (closed circles). (b) Inhibition of IL-1 induced 
PGE2 production by iL-ira. Human dermal fibroblasts were. stimu- 
lated for 24 h with IL-I~, and the culture sulmrnatant assayed for 
PGE: production. Increasing concentration'~ of IL-lra were tested for 
their ability to inhibit his IL-I induced PGE2 production. 
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whether this molecule indeed inhibits IL-1 mediated ac- 
tivation and has no agonist activity, a PGE2 production 
assay was performed. The recombinant IL-lra totally 
inhibited PGE,. production by human dermal fibrob- 
lasts induced by 50 pM IL-I/~ (Fig. 2b). Half maximal 
inhibition was obtained with a 25-fold molar excess of 
the IL-1 receptor antagonist. This is in line with the 
results obtained by other investigators, where a 10 to 
100-fold excess was required (see refs. in [7]). 
To establish whether or not the four cys~eines present 
in IL-lra are disulphide-linked, the recombinant pro- 
tein was digested (without prior reduction) with the 
protease V8 and the N-termini of the major peptides 
obtained were sequenced. Human IL-lra contains four 
cysteines at amino acid positions 66, 69, 116 and 122 
(numbering of the amino acids is according to the IL- 
Ira eDNA derived sequence [2]). Two peptides were 
obtained which contained two cysteines each. One cov- 
ered the amino acids from position 45 to 75 and the 
second from 113 to 126. As these two peptides were not 
eluted in the same fraction from reverse phase chroma- 
tography, they are not erosslinked by disulphide 
bridges. To determine whether neighbouring cysteines 
were disulphide linked, IL-lra (135 ~g) in 4 M guani- 
dine, 0.2 M Tris-HCl, pH 8.2 was radioalkylated with 
[3H]iodoacetie acid (50/.tCi) (Amersham), with or with- 
out prior reduction by dithiothreitoi. Uptake of radio- 
activity was identical with or without prior reduction, 
indicating that none of the 4-eysteines i involved in 
disulphide linkage, and that all 4 are titratable with 
iodoaectic acid in denaturing conditions. NMR-derived 
secondary 1L-lra structure [11] supports the view, that 
disulphide linkages are not formed. 
IL-lra shows, respectively, 18% and 26% amino acid 
identity with IL-I~ and IL-I~ [3]. IL-10~ has only one 
eysteine and therefore no disulphide bridges. In the IL- 
lfl molecule two cysteine residues are present, but crys- 
tal structure data clearly show that they are not dis- 
ulphide linked [12]. Since this recombinant IL-lra pro- 
tein is as functionally active as the native protein, this 
strongly indicates that the native form of IL-lra also 
lacks disulphide bridges. 
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